Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PATADAY ONCE DAILY RELIEF vs ACETAMINOPHEN AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Olopatadine is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits release of histamine and other mediators from mast cells, reducing allergic conjunctivitis symptoms.
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Treatment of ocular itching associated with allergic conjunctivitis (FDA-approved)
Mild to moderate pain,Pain accompanied by fever
1 drop in each affected eye once daily. The ophthalmic solution is 0.2% (olopatadine hydrochloride).
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
Terminal elimination half-life is approximately 9 hours; allows twice-daily dosing for sustained symptom control.
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Olopatadine undergoes minimal hepatic metabolism; approximately 60-70% excreted unchanged in urine. Metabolites include N-demethylated and N-oxide derivatives; CYP450 enzymes not significantly involved.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Primarily renal excretion: approximately 60% of dose excreted unchanged in urine; fecal elimination accounts for less than 10%.
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Approximately 70-80% bound to plasma proteins, primarily albumin.
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
Volume of distribution is approximately 1.4 L/kg, indicating distribution into total body water.
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
Ocular bioavailability is low due to nasolacrimal drainage and systemic absorption; systemic bioavailability from ocular dose is less than 5%.
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
No dosage adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), use with caution as safety has not been established.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
No dosage adjustment required for mild to moderate hepatic impairment. For severe hepatic impairment (Child-Pugh class C), use with caution as safety has not been established.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
For children 2 years of age and older: 1 drop in each affected eye once daily. Safety and efficacy in children under 2 years have not been established.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
No specific dosage adjustment required. Use the same dose as for younger adults. Overall, no differences in safety or efficacy were observed between elderly and younger patients.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
None.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
Not for injection; for topical ophthalmic use only.,Do not wear contact lenses if eyes are red; wait at least 10 minutes after instillation before inserting lenses.,Contains benzalkonium chloride which may be absorbed by soft contact lenses.,May cause transient stinging or burning upon instillation.
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Hypersensitivity to olopatadine or any component of the formulation.
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
No known food interactions. No dietary restrictions required.
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
Pregnancy Category C. In animal studies, olopatadine (0.4 mg/kg/day SC) produced no teratogenic effects but caused reduced fetal weight and delayed ossification at maternally toxic doses. No adequate human studies exist. Risk cannot be ruled out; use only if benefit outweighs potential fetal risk.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
Olopatadine is excreted in rat milk at concentrations ~2.4 times higher than maternal plasma. No human data on M/P ratio. Caution advised; consider risk-benefit and monitor infant for anticholinergic effects.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
No pharmacokinetic studies in pregnancy. No dose adjustment recommended based on available data. Use at lowest effective dose and shortest duration.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
Pataday Once Daily Relief contains olopatadine 0.2%, a mast cell stabilizer and antihistamine. For optimal efficacy, instruct patients to administer one drop in each affected eye once daily. Shake bottle before use. Wait at least 5 minutes before inserting contact lenses due to preservative (benzalkonium chloride). Monitor for transient burning or stinging upon instillation. Not for injection. Patients using additional ophthalmic products should separate by 5 minutes.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
Do not touch dropper tip to any surface to avoid contamination.,Remove contact lenses before use; wait 10 minutes before reinserting.,May cause temporary blurred vision; avoid driving until vision clears.,If you miss a dose, use it as soon as remembered, but skip if near next dose.,Keep bottle tightly closed when not in use; store at room temperature.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
No interactions on record
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PATADAY ONCE DAILY RELIEF vs ACETAMINOPHEN AND CODEINE PHOSPHATE, answered by our medical review team.
PATADAY ONCE DAILY RELIEF is a Ophthalmic Antiallergic Agent that works by Olopatadine is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits release of histamine and other mediators from mast cells, reducing allergic conjunctivitis symptoms.. ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PATADAY ONCE DAILY RELIEF and ACETAMINOPHEN AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PATADAY ONCE DAILY RELIEF is: 1 drop in each affected eye once daily. The ophthalmic solution is 0.2% (olopatadine hydrochloride).. The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PATADAY ONCE DAILY RELIEF and ACETAMINOPHEN AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PATADAY ONCE DAILY RELIEF is classified as Category C. Pregnancy Category C. In animal studies, olopatadine (0.4 mg/kg/day SC) produced no teratogenic effects but caused reduced fetal weight and delayed ossification at maternally toxic. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.